Please ensure Javascript is enabled for purposes of website accessibility

Ionis Pharmaceuticals' Revenues Rose 85% in 2019

By Taylor Carmichael - Feb 26, 2020 at 2:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotechnology company's license fees increased almost 400% to $490 million.

Ionis Pharmaceuticals (IONS -1.66%) reported its fourth-quarter and full-year results on Wednesday, and surpassed its revenue and earnings estimates for the year. The company announced over $1.1 billion in revenues for 2019, up from $600 million in 2018. Ionis had $494 million in revenues in the fourth quarter alone. 

For 2019, the company reported more than $400 million in net income. And it added another $400 million to its balance sheet, upping the company's cash cushion to $2.5 billion. 

image of drug capsule opening

Image source: Getty Images

Turning R&D into cash

Ionis has three drugs on the market. The one bringing in the most revenue is Spinraza, a treatment for spinal muscular atrophy. It's marketed by Biogen (BIIB -0.44%), which pays royalties to Ionis. In 2019, those payments amounted to $293 million dollars. All in all, Ionis reported $352 million in royalties and other sales revenues for the year. 

Most of Ionis' revenues came from its R&D program: It made $771 million from its pipeline in 2019. Pharmaceutical companies are paying a lot of cash to get access to the 28 drugs it has in clinical trials.  For 2019, that broke down to $146 million in upfront payments (amortized); $115 million in milestone payments (made when drugs advance in clinical trials); and $490 million in license fees. Income from that last source was up dramatically from 2018's $102 million figure. 

Ionis has multiple deals in place with big pharma players, including  collaborations with Roche, Pfizer, Novartis, Bayer, AstraZeneca, and GlaxoSmithKline.

Ionis Pharmaceuticals stock was up by more than 1% in mid-afternoon trading Wednesday. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$38.60 (-1.66%) $0.65
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$211.00 (-0.44%) $0.93

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.